Impact of Antimicrobial Dipping Solutions on Postoperative Infection Rates in Patients With Diabetes Undergoing Primary Insertion of a Coloplast Titan Inflatable Penile Prosthesis.


Journal

The journal of sexual medicine
ISSN: 1743-6109
Titre abrégé: J Sex Med
Pays: Netherlands
ID NLM: 101230693

Informations de publication

Date de publication:
10 2020
Historique:
received: 14 03 2020
revised: 06 07 2020
accepted: 15 07 2020
pubmed: 19 8 2020
medline: 22 12 2020
entrez: 19 8 2020
Statut: ppublish

Résumé

Modern-day penile prostheses use infection retardant coating to decrease rates of postoperative infection, subsequently reducing explantation and revision rates as well. The Coloplast Titan models are dipped into antimicrobial solutions right before implantation, and the components used for dipping can be tailored toward the patient. To compare infection, explantation, and revision rates among different dipping solutions used before implantation for patients with diabetes receiving a Coloplast Titan implant. We systematically reviewed 932 patients with diabetes receiving a primary penile implant across 18 different centers from the period April 2003 to August 2018. Of those patients, 473 received a Coloplast device, whereas 459 received an AMS device. Data regarding the type of antimicrobial solution used before implantation were recorded for 468 patients receiving a Coloplast Titan, including whether or not they suffered a postoperative infection and if they underwent explantation and/or revision. Outcome rates were compared using Fisher's exact and Pearson's chi-square tests, and logistic regression modeling was performed to account for covariates. The main outcome measures of this study were postoperative infection, explantation, and revision rates. Of the total 932 patients reviewed, 33 suffered a postoperative infection. Of 468 patients receiving Coloplast implants, there was a 3.4% infection rate. The most commonly used antibiotic combination before dipping was vancomycin + gentamicin (59.0%). There was a significantly lower rate of postoperative infection, explantation, and revision when vancomycin + gentamicin was used than those associated with the use of all other dipping solutions ([1.4% vs 6.4%; P = .004], [1.1% vs 8.3%; P < .001], and [2.5% vs 12.5; P < .001], respectively). After adjusting for age, body mass index, preoperative blood glucose level, and hemoglobin A1c, the use of other dips was an independent predictor of postoperative infection (odds ratio: 0.191; P = .049). The inclusion of rifampin in the dipping solution trended toward being a significant risk factor for infection (P = .057). Including antifungals in the dipping solution did not affect infection (P = .414), explantation (P = .421), or revision (P = .328) rates. Vancomycin + gentamicin was the most efficacious combination of antibiotics used for dipping in terms of preventing postoperative infection and subsequent explantation and revision. Data were sampled across multiple institutions providing a large sample that may be more representative of the population of interest. A key limitation of the study was its retrospective nature, which prevented us from controlling certain variables. The use of rifampin did not provide the same type of protection, possibly representing a shift in resistance patterns of common bacteria responsible for device infection. Towe M, Huynh LM, Osman MM, et al. Impact of Antimicrobial Dipping Solutions on Postoperative Infection Rates in Patients With Diabetes Undergoing Primary Insertion of a Coloplast Titan Inflatable Penile Prosthesis. J Sex Med 2020;17:2077-2083.

Sections du résumé

BACKGROUND
Modern-day penile prostheses use infection retardant coating to decrease rates of postoperative infection, subsequently reducing explantation and revision rates as well. The Coloplast Titan models are dipped into antimicrobial solutions right before implantation, and the components used for dipping can be tailored toward the patient.
AIM
To compare infection, explantation, and revision rates among different dipping solutions used before implantation for patients with diabetes receiving a Coloplast Titan implant.
METHODS
We systematically reviewed 932 patients with diabetes receiving a primary penile implant across 18 different centers from the period April 2003 to August 2018. Of those patients, 473 received a Coloplast device, whereas 459 received an AMS device. Data regarding the type of antimicrobial solution used before implantation were recorded for 468 patients receiving a Coloplast Titan, including whether or not they suffered a postoperative infection and if they underwent explantation and/or revision. Outcome rates were compared using Fisher's exact and Pearson's chi-square tests, and logistic regression modeling was performed to account for covariates.
OUTCOMES
The main outcome measures of this study were postoperative infection, explantation, and revision rates.
RESULTS
Of the total 932 patients reviewed, 33 suffered a postoperative infection. Of 468 patients receiving Coloplast implants, there was a 3.4% infection rate. The most commonly used antibiotic combination before dipping was vancomycin + gentamicin (59.0%). There was a significantly lower rate of postoperative infection, explantation, and revision when vancomycin + gentamicin was used than those associated with the use of all other dipping solutions ([1.4% vs 6.4%; P = .004], [1.1% vs 8.3%; P < .001], and [2.5% vs 12.5; P < .001], respectively). After adjusting for age, body mass index, preoperative blood glucose level, and hemoglobin A1c, the use of other dips was an independent predictor of postoperative infection (odds ratio: 0.191; P = .049). The inclusion of rifampin in the dipping solution trended toward being a significant risk factor for infection (P = .057). Including antifungals in the dipping solution did not affect infection (P = .414), explantation (P = .421), or revision (P = .328) rates.
CLINICAL IMPLICATIONS
Vancomycin + gentamicin was the most efficacious combination of antibiotics used for dipping in terms of preventing postoperative infection and subsequent explantation and revision.
STRENGTHS AND LIMITATIONS
Data were sampled across multiple institutions providing a large sample that may be more representative of the population of interest. A key limitation of the study was its retrospective nature, which prevented us from controlling certain variables.
CONCLUSION
The use of rifampin did not provide the same type of protection, possibly representing a shift in resistance patterns of common bacteria responsible for device infection. Towe M, Huynh LM, Osman MM, et al. Impact of Antimicrobial Dipping Solutions on Postoperative Infection Rates in Patients With Diabetes Undergoing Primary Insertion of a Coloplast Titan Inflatable Penile Prosthesis. J Sex Med 2020;17:2077-2083.

Identifiants

pubmed: 32807707
pii: S1743-6095(20)30758-X
doi: 10.1016/j.jsxm.2020.07.009
pii:
doi:

Substances chimiques

Gentamicins 0

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2077-2083

Informations de copyright

Copyright © 2020 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.

Auteurs

Maxwell Towe (M)

Division of Urology, University of Maryland, School of Medicine, Baltimore, MD, USA. Electronic address: maxwell.towe@som.umaryland.edu.

Linda M Huynh (LM)

Department of Urology, University of California, Irvine Medical Center, Orange, CA, USA.

Mohamad M Osman (MM)

Department of Urology, University of California, Irvine Medical Center, Orange, CA, USA.

Farouk M El-Khatib (FM)

Department of Urology, University of California, Irvine Medical Center, Orange, CA, USA.

Robert Andrianne (R)

Service d'urologie, Centre Hospitalier Universitaire de Liège, Liège, Belgium.

Gregory Barton (G)

Division of Urology, Duke University Medical Center, Durham, NC, USA.

Gregory Broderick (G)

Department of Urology, Mayo Clinic, Jacksonville, FL, USA.

Arthur L Burnett (AL)

Department of Urology, The Johns Hopkins Hospital, Baltimore, MD, USA.

Jeffrey D Campbell (JD)

Department of Urology, The Johns Hopkins Hospital, Baltimore, MD, USA.

Jonathan Clavell-Hernandez (J)

Department of Urology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

Jessica Connor (J)

Department of Urology, Hackensack University Medical Center, Hackensack, NJ, USA.

Martin Gross (M)

Section of Urology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.

Ross Guillum (R)

Department of Urology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

Amy I Guise (AI)

Department of Urology, Medical College of Wisconsin, Milwaukee, WI, USA.

Georgios Hatzichristodoulou (G)

Department of Urology, Julius-Maximilians-University of Würzburg, Würzburg, Germany.

Gerard D Henry (GD)

ArkLaTex Urology, Bossier City, LA, USA.

Tung-Chin Hsieh (TC)

Department of Urology, UC San Diego Health System, San Diego, CA, USA.

Lawrence C Jenkins (LC)

Department of Urology, The Ohio State University, Columbus, OH, USA.

Christopher Koprowski (C)

Department of Urology, UC San Diego Health System, San Diego, CA, USA.

Kook B Lee (KB)

Sewum Prosthetic Urology Center of Excellence, Seoul, South Korea.

Aaron Lentz (A)

Division of Urology, Duke University Medical Center, Durham, NC, USA.

Ricardo M Munarriz (RM)

Department of Urology, Boston University Medical Center, Boston, MA, USA.

Daniar Osmonov (D)

Department of Urology, University Hospital Schleswig Holstein, Campus Kiel, Germany.

Shu Pan (S)

Department of Urology, Boston University Medical Center, Boston, MA, USA.

Kevin Parikh (K)

Department of Urology, Mayo Clinic, Jacksonville, FL, USA.

Sung Hun Park (SH)

Sewum Prosthetic Urology Center of Excellence, Seoul, South Korea.

Amir S Patel (AS)

Department of Urology, Einstein Healthcare Network, Fox Chase Cancer Center, Philadelphia, PA, USA.

Paul Perito (P)

Perito Urology, Coral Gables, FL, USA.

Hossein Sadeghi-Nejad (H)

Department of Urology, Hackensack University Medical Center, Hackensack, NJ, USA.

Maxime Sempels (M)

Service d'urologie, Centre Hospitalier Universitaire de Liège, Liège, Belgium.

Jay Simhan (J)

Department of Urology, Einstein Healthcare Network, Fox Chase Cancer Center, Philadelphia, PA, USA.

Run Wang (R)

Department of Urology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

Faysal A Yafi (FA)

Department of Urology, University of California, Irvine Medical Center, Orange, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH